We look at cheaper alternatives to drugs like Keytruda, Novo Nordisk’s GLP-1 deal to make the next-gen Wegovy pill and more in this week’s edition of InnovationRx.
Get the latest international news and world events from around the world.
AI Is The 21st Century Force Multiplier
Ease see my latest Forbes article and have a great weekend! Chuck Brooks by Chuck Brooks.
#artificialIntelligence #ai #future #tech Forbes
AI is redefining power, productivity, security, and sovereignty. Dual-use, convergent, and autonomous AI is the 21st-century force multiplier. Not only is technology advancing, but civilization is about to change.
The 1956 Dartmouth Conference invented the term “artificial intelligence.” Alan Turing and other pioneers shaped the conceptualization of AI. The first systems used symbolic logic and determinism. Certain expert systems excelled but struggled in dynamic, uncertain environments. Fragility, computational capacity, and data accessibility caused “AI winters.”
⚖️ We Are All Middle Managers of Aliens Now: On the 2026 International AI Safety Report — and why you should read it
Review of International AI Safety Report 2026.
Heliox unpacks the 2026 International AI Safety Report — the definitive global scientific consensus on AI risk — in forty minutes of evidence-grounded, empathetically framed conversation. From jagged AI genius to geopolitical fracture to cognitive atrophy, this episode makes the most consequential technology document of 2026 genuinely accessible.
The Virtual Biotech: A Multi-Agent AI Framework for Therapeutic Discovery and Development
Drug discovery and development requires integrating diverse evidence across biological scales and data modalities. However, relevant data, tools, and expertise remain fragmented across teams and organizations, making integration difficult. To address these challenges, we introduce the Virtual Biotech, a coordinated team of AI agents that mirrors the structure of human therapeutic research organizations to support end-to-end computational discovery. The Virtual Biotech is led by a Chief Scientific Officer agent that receives scientific queries, delegates them to domain-specialized scientist agents, and integrates their outputs through data-driven reasoning. Scientist agents leverage complementary tools and knowledge sources spanning statistical genetics, functional genomics, pathways and interactions, chemoinformatics, disease biology, and clinical data. We showcase the Virtual Biotech across three translational applications. First, the agents autonomously annotated and analyzed outcomes from 55,984 clinical trials to identify genomic features of drug targets associated with trial success. More than 37,000 clinical-trialist agents curated structured trial outcomes and linked targets to multi-omic annotations, including cell-type-specific features derived by the agents from single-cell RNA-sequencing atlases. The agents discovered that drugs targeting cell-type-specific genes were 40% more likely to progress from Phase I to Phase II and 48% more likely to reach market (Phase IV), while exhibiting 32% lower adverse event rates. Second, the Virtual Biotech evaluated B7-H3 as a lung cancer target, integrating statistical genetics, single-cell, spatial, and clinicogenomic evidence to propose an antibody–drug conjugate strategy while identifying key liabilities and differentiation opportunities. Third, the platform analyzed a terminated ulcerative colitis trial targeting OSMR β to infer potential failure mechanisms and proposed biomarker-guided enrollment strategies to address precision-medicine gaps. Together, these results illustrate how the Virtual Biotech can enable more transparent, efficient, and comprehensive multi-scale therapeutic analyses, helping to accelerate early-stage drug discovery workflows while keeping human scientists in the loop.
The authors have declared no competing interest.
Balancing IL-17–mediated protection and IFN-γ–driven pathology at mucocutaneous barriers
Controlling mucocutaneous barriers by cytokines.
Impaired IL-17 leads to mucocutaneous bacterial and fungal infections, whereas enhanced IL-17 promotes psoriasis and periodontitis.
Interferon (IFN)-γ deficiency causes infections by intracellular pathogens, whereas exacerbated mucosal IFN-γ activity promotes oral candidiasis, even when IL-17 responses are intact.
JAK inhibition in autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy remits oral candidiasis and multiorgan autoimmunity.
IFN-γ drives Candida auris skin infection by impairing the epithelial barrier. Excess IFN-γ, tumor necrosis factor, and types I/III IFN activities contribute to pathology during bacterial and protozoan skin infections and pulmonary viral, bacterial, mycobacterial, and fungal infections.
Although immune deficiency causes mucosal infection, epithelial disruption by immunopathology represents a novel and underappreciated mechanism of infection susceptibility at barrier sites. sciencenewshighlights ScienceMission https://sciencemission.com/Balancing-IL-17
Steroid-Refractory Pembrolizumab-Induced Haemophagocytic Lymphohistiocytosis (HLH) Successfully Treated With Anakinra: A Case Report
This stage IV lung cancer patient developed: persistent fever thrombocytopenia multiorgan dysfunction steroid-refractory course.
A high H-score led to the diagnosis: ICI-associated HLH. She improved rapidly with anakinra after failing steroids.
Takeaway: In immunotherapy patients, extreme hyperferritinaemia should trigger HLH evaluation early.
Would you have escalated to anakinra…or tried second-line steroids first?
Read more here.
Immune checkpoint inhibitors (ICIs) are increasingly used in advanced malignancies but can cause rare, severe immune-related adverse events (irAEs). Haemophagocytic lymphohistiocytosis (HLH) is a life-threatening hyperinflammatory syndrome infrequently reported with ICIs and often challenging to diagnose. We report a case of a woman in her 60s with stage IV lung adenocarcinoma treated with pembrolizumab-based chemoimmunotherapy who developed recurrent, steroid-refractory immune-related hepatitis and pneumonitis. Twenty-four weeks after starting pembrolizumab, she presented with persistent fever, thrombocytopenia, extreme hyperferritinaemia (ferritin >33,500 µg/L), and progressive multiorgan dysfunction. Despite overlap with other irAEs and infection, a high H-score prompted evaluation for HLH, confirmed on bone marrow biopsy with haemophagocytosis.